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BACKGROUND: There is evidence to suggest that diabetes may increase the risk of incidence and mortality from cancer.
METHODS: In a cohort study using record-linkage health-care datasets for Tayside, Scotland in 1993–2004, we followed up 9577 newly
diagnosed patients with type 2 diabetes, and two matched non-diabetic comparators, in the national cancer register.
RESULTS AND CONCLUSIONS: The risk ratio for any cancer, adjusted for deprivation, was 0.99 (95%CI 0.90–1.09). Significantly increased
risks were observed for pancreatic, liver and colon cancer.
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Whether there was an increased prevalence of cancer associated
with insulin use was questioned in the early twentieth century
(Marble, 1934), and there is a growing body of evidence suggesting
that diabetes increases the risk of the incidence and mortality from
certain cancers. These include pancreatic and liver cancer,
colorectal cancer, breast cancer, bladder cancer, cancer of the
kidney and endometrial cancer (Wideroff et al, 1997; Coughlin
et al, 2004; Rousseau et al, 2006; Kuriki et al, 2007). However, the
results of studies of diabetes and cancer have been very mixed with
many not distinguishing between type 1 and type 2 diabetes
(Wideroff et al, 1997), or have defined groups according to
treatment (Swerdlow et al, 2005). In some studies, the basis for
diabetes diagnosis is self-report (Coughlin et al, 2004), in others it
is clinical (Saydah et al, 2003). Studies have been both retro-
spective (Kuriki et al, 2007) and prospective, with some
prospective studies following up from diagnosis of diabetes
(Ragozzino et al, 1982); another followed up a cross-sectional
sample of patients (Swerdlow et al, 2005). In this study, we present
the risks of different cancers following diagnosis of type 2 diabetes
in Tayside, Scotland, using a standardised methodology.
MATERIALS AND METHODS
This cohort study was carried out using the datasets of the Health
Informatics Centre (HIC), University of Dundee, which developed
the record linkage of routinely collected health-care datasets to
facilitate epidemiological and other health research in the
population of Tayside Health Board, Scotland (approximately
population 400 000) (Evans et al, 1995). A diabetes clinical
information system was used to identify all patients registered
with any Tayside GP practice who were diagnosed with type 2
diabetes in 1993–2004 (Morris et al, 1997). Their date of diagnosis
was defined as their study index date. Any patient who had an
earlier record of cancer diagnosis on the Scottish national cancer
registry (SMR6) was excluded (Scottish Cancer Registry, 2009).
For each eligible patient with type 2 diabetes, two non-diabetic
comparators were selected at random from computerised lists of
patients registered with primary care, matched for age (within 1
year), sex and GP practice. The index date of the comparator was
that of its matched diabetic patient; and the comparator had to be
alive and have no earlier cancer diagnosis on this date.
Diabetic patients and their comparators were followed for a
maximum of 11 years in a survival analysis to the study end date
(1st January 2004). The primary outcome was diagnosis of
malignant cancer on SMR6; deaths were also identified. The
relationship between type 2 diabetes and cancer was assessed in a
Cox regression unadjusted, and then in a multivariable model
adjusted for deprivation (measured using deciles of a postcode
score for material deprivation) (Carstairs, 1990). This was repeated
for specific cancer types according to the ICD10 diagnosis code
recorded on SMR6.
Statistical analyses were performed using SPSS (Statistical
Package for Social Scientist) 15.0 software programme. All data
were anonymised for analysis. Ethical approval was obtained from
the Multi-Centre Research and Ethics Committee for Scotland.
RESULTS
The study population comprised 9577 people registered with any
Tayside general practice diagnosed with type 2 diabetes between
1993 and 2004, and 19 154 non-diabetic comparators, of these,
53.3% were male, and the mean age at index date was 62 years; 661
(6.9%) of patients with diabetes were diagnosed with cancer, as
recorded on SMR6, during follow-up (mean length of follow-up
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1417 days), compared with 1364 (7.1%) of the comparators (mean
follow-up 1476 days). Of the diabetic patients, 12.5% died and
8.3% of the comparators died.
The unadjusted risk ratio for any diagnosis of cancer was 1.01
(95% CI 0.92–1.11) for diabetic patients. After adjusting for
deprivation, it reduced to 0.99 (95% CI 0.90–1.09) (Table 1). Risk
ratios were determined for specific cancers, presented in Table 1 in
decreasing order of frequency (accounting for 79% of all cancers).
There were significant increased risks associated with type 2
diabetes and of colon, pancreatic and cancer liver only. The results
were largely unchanged after excluding outcomes in the first year
of follow-up.
DISCUSSION
This study finds no evidence that patients with type 2 diabetes
have an overall increased risk of cancer compared with non-
diabetic people, with adjusted risk ratios approaching unity.
However, there was an increased risk of certain specific cancers
that, because uncommon, did not have a substantial effect on the
overall risk ratio.
Patients with type 2 diabetes were three times more likely to
develop pancreatic cancer than non-diabetic people, a widely
reported association (Coughlin et al, 2004; Rousseau et al, 2006;
Kuriki et al, 2007). Although type 2 diabetes could be a risk factor
for pancreatic cancer (Wideroff et al, 1997), it is more likely to be a
consequence (reverse causality) (Gullo et al, 1994), being stronger
among recently diagnosed patients. The three-fold increased risk
of liver cancer is also similar to earlier reports (Wideroff et al,
1997; Rousseau et al, 2006), some of which have adjusted for
confounding by alcohol and viral hepatitis (Davila et al, 2005).
However, the risk is higher after excluding patients diagnosed in
the year following diabetes, suggesting that reverse causality is
unlikely to be the explanation here.
Our slight increased risk of 1.46 for cancer of the colon is in line
with a recent meta-analysis (Larsson et al, 2005). Other studies
have observed similar risks, some of which were not significant
perhaps owing to small sample size (Wideroff et al, 1997; Coughlin
et al, 2004; Rousseau et al, 2006). In contrast, we observed no
increased risk for rectal cancer, consistent with the lack of
statistically significant increased risk in the Nurses’ Health Study
(Hu et al, 1999).
This study provided no evidence for associations between
type 2 diabetes and other cancer types. A Danish study
found increased risks of kidney and endometrial cancer (Wideroff
et al, 1997), these cancers were not common in our cohort and
larger sample sizes would be needed to detect an associated risk.
We also found no increase of breast or bladder cancer, despite a
US finding of excess mortality (Coughlin et al, 2004). However,
associations with mortality could be confounded by survival-
related factors.
We are confident in the validity of our data sources, which have
been widely used in epidemiological studies, whereas SMR6 is a
national, validated dataset. It also allowed estimation of risks of
cancer incidence, using precise dates of diagnosis. The study’s
main limitation was lack of information on lifestyle-related
confounders, although we were able to adjust for deprivation.
Patients with diabetes may have a higher prevalence of lifestyle-
related risk factors for cancer, such as obesity (Hjartaker et al,
2008). However, we found no increased risks of many cancers
despite these potential confounders, thereby increasing confidence
in the conclusions.
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